Physician
Aurora Advanced Healthcare, INC.
Aurora Advanced Healthcare, INC. was paid $28.21M by Medicaid between Jan 2018 and Dec 2024, across 276 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 32% of everything it billed.
33Billing provider infoAURORA ADVANCED HEALTHCARE, INC.
MILWAUKEE, WI 53209
MILWAUKEE, WI 53209
33aNPI1265629133assigned 09/25/2007
33bProvider typeAllergy & Immunology Physician
28Total paid$28.21M
24GClaims1,141,449
24DCodes billed276
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Allergy & Immunology Physician providers in Wisconsin
Rank by total paid#2 of 11
Median peer was paid$26K
This provider vs. median1,071×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 128,703 | $3.10M | |
| 2019 | 138,196 | $3.21M | |
| 2020 | 119,410 | $2.92M | |
| 2021 | 185,598 | $4.39M | |
| 2022 | 211,208 | $4.90M | |
| 2023 | 213,420 | $4.98M | |
| 2024incomplete | 144,914 | $4.71M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 32% | 212,882 | 195,229 | $9.10M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 208,400 | 193,028 | $6.05M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.0% | 16,007 | 14,964 | $850K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.9% | 5,298 | 4,795 | $831K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.7% | 24,466 | 22,918 | $773K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.3% | 3,280 | 2,890 | $652K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.9% | 7,665 | 7,081 | $525K |
| 20610 | 1.8% | 12,017 | 10,039 | $503K | |
| 99000 | 1.5% | 115,395 | 103,634 | $420K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 20,817 | 9,954 | $418K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 52,766 | 48,705 | $372K |
| 0240U | 1.3% | 11,848 | 10,955 | $370K |
264 more codes
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.2% | 6,008 | $348K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.0% | 4,898 | $290K |
| 80053 | Comprehensive metabolic panel | 1.0% | 30,688 | $283K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 989 | $272K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 4,804 | $254K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 3,794 | $220K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 7,849 | $217K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 2,941 | $217K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 3,467 | $201K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,157 | $200K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,992 | $188K |
| 87210 | <1% | 29,409 | $155K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,714 | $148K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 10,137 | $148K |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 9,567 | $147K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 5,094 | $146K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 181 | $134K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 3,404 | $131K |
| 81025 | <1% | 16,220 | $127K | |
| 90686 | <1% | 14,177 | $125K | |
| 80050 | General health panel | <1% | 2,896 | $122K |
| 81001 | <1% | 38,013 | $112K | |
| 43235 | <1% | 843 | $107K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,912 | $106K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 4,415 | $99K |
| 99254 | <1% | 1,520 | $98K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 4,164 | $96K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,635 | $90K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,202 | $86K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 14,634 | $83K |
| 99243 | <1% | 1,389 | $80K | |
| 91322 | <1% | 714 | $75K | |
| 3008F | <1% | 8,406 | $75K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,982 | $74K |
| 99223 | Prolong inpt eval add15 m | <1% | 1,646 | $70K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 2,564 | $69K |
| 11721 | <1% | 5,586 | $65K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,097 | $63K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,840 | $57K |
| 85027 | <1% | 8,577 | $50K | |
| 92015 | Determination of refractive state | <1% | 8,203 | $47K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 975 | $45K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,829 | $44K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,785 | $43K |
| 98940 | <1% | 3,517 | $42K | |
| 93000 | <1% | 3,295 | $41K | |
| 0124A | <1% | 1,229 | $41K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 498 | $39K |
| 0001A | <1% | 898 | $33K | |
| 73562 | <1% | 1,674 | $33K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 140 | $32K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,116 | $32K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 741 | $32K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 472 | $30K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 7,360 | $27K |
| 76830 | Ultrasound, transvaginal | <1% | 350 | $27K |
| 90480 | <1% | 801 | $24K | |
| 64483 | <1% | 195 | $22K | |
| 81003 | <1% | 10,632 | $22K | |
| 0002A | <1% | 570 | $21K | |
| 0071A | <1% | 581 | $21K | |
| 90677 | <1% | 371 | $21K | |
| 83690 | <1% | 3,177 | $20K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 277 | $20K |
| 84702 | <1% | 1,695 | $20K | |
| 83880 | <1% | 734 | $19K | |
| 98942 | <1% | 861 | $18K | |
| 0054A | <1% | 515 | $17K | |
| 0051A | <1% | 498 | $17K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 2,099 | $17K |
| 73030 | <1% | 960 | $17K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 771 | $16K |
| 99385 | <1% | 304 | $16K | |
| 85610 | <1% | 4,863 | $16K | |
| 85652 | <1% | 6,644 | $16K | |
| 80076 | <1% | 2,253 | $16K | |
| 99152 | <1% | 589 | $15K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 752 | $15K |
| 90688 | <1% | 1,682 | $15K | |
| 0072A | <1% | 393 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 984 | $14K |
| 85379 | <1% | 1,604 | $14K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 164 | $14K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 648 | $13K |
| 0004A | <1% | 355 | $12K | |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | <1% | 13 | $12K |
| 91321 | <1% | 223 | $12K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 223 | $12K |
| 64721 | <1% | 52 | $12K | |
| 99460 | <1% | 137 | $11K | |
| 90656 | <1% | 656 | $11K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 666 | $11K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 539 | $11K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,228 | $11K |
| 93793 | <1% | 2,860 | $11K | |
| 11720 | <1% | 1,529 | $11K | |
| 90670 | <1% | 2,575 | $11K | |
| 84703 | <1% | 1,442 | $11K | |
| 84484 | <1% | 1,061 | $11K | |
| 82565 | <1% | 2,470 | $10K | |
| 0052A | <1% | 293 | $10K | |
| 93356 | <1% | 646 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,515 | $10K |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 1,836 | $10K |
| 31575 | <1% | 170 | $10K | |
| 73502 | <1% | 539 | $9K | |
| 80061 | Lipid panel | <1% | 1,107 | $9K |
| 83735 | <1% | 1,776 | $9K | |
| 94010 | <1% | 265 | $9K | |
| 99242 | <1% | 187 | $8K | |
| J7325 | Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | <1% | 48 | $8K |
| 99188 | <1% | 626 | $8K | |
| 36416 | <1% | 2,904 | $7K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 249 | $7K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 31 | $7K |
| 99070 | <1% | 694 | $7K | |
| 92557 | <1% | 301 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,223 | $7K |
| 0012A | <1% | 185 | $7K | |
| 99205 | Prolong outpt/office vis | <1% | 85 | $7K |
| 0011A | <1% | 205 | $7K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 440 | $7K |
| 0064A | <1% | 195 | $7K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 48 | $7K |
| 69210 | <1% | 767 | $6K | |
| 99245 | <1% | 92 | $6K | |
| 64615 | <1% | 95 | $6K | |
| 90647 | <1% | 855 | $6K | |
| 0111A | <1% | 175 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,179 | $6K |
| 90723 | <1% | 853 | $6K | |
| 96127 | <1% | 1,510 | $6K | |
| 90732 | <1% | 74 | $6K | |
| 82550 | <1% | 998 | $6K | |
| 86308 | <1% | 1,107 | $6K | |
| 99284 | Emergency room visit (serious) | <1% | 143 | $5K |
| G0127 | Trimming of dystrophic nails, any number | <1% | 716 | $5K |
| 74018 | <1% | 274 | $5K | |
| 84550 | <1% | 1,456 | $5K | |
| 82950 | <1% | 1,040 | $5K | |
| 73564 | <1% | 222 | $5K | |
| 82247 | <1% | 968 | $5K | |
| 72100 | <1% | 191 | $5K | |
| 99442 | <1% | 297 | $5K | |
| 92567 | <1% | 378 | $5K | |
| 64493 | <1% | 52 | $5K | |
| 85018 | <1% | 1,920 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 435 | $4K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 15 | $4K |
| 73630 | <1% | 184 | $4K | |
| 99441 | <1% | 461 | $4K | |
| 73610 | <1% | 153 | $4K | |
| 90673 | <1% | 76 | $4K | |
| 99443 | <1% | 199 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 52 | $4K |
| 97161 | <1% | 91 | $4K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 126 | $4K |
| 20611 | <1% | 67 | $3K | |
| 95886 | <1% | 45 | $3K | |
| 97162 | <1% | 80 | $3K | |
| 62323 | <1% | 29 | $3K | |
| 0154A | <1% | 89 | $3K | |
| 0134A | <1% | 89 | $3K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 189 | $3K |
| 82150 | <1% | 450 | $3K | |
| 90715 | <1% | 116 | $3K | |
| 0112A | <1% | 81 | $3K | |
| Q0112 | All potassium hydroxide (koh) preparations | <1% | 469 | $3K |
| 90680 | <1% | 572 | $3K | |
| 90633 | <1% | 644 | $2K | |
| 82728 | <1% | 300 | $2K | |
| 85014 | <1% | 1,019 | $2K | |
| 82248 | <1% | 476 | $2K | |
| 90651 | <1% | 361 | $2K | |
| 95923 | <1% | 29 | $2K | |
| 99201 | <1% | 80 | $2K | |
| 90698 | <1% | 610 | $2K | |
| 0121A | <1% | 60 | $2K | |
| 87563 | <1% | 87 | $2K | |
| 99283 | Emergency room visit (moderate) | <1% | 80 | $2K |
| 73110 | <1% | 70 | $2K | |
| 84100 | <1% | 598 | $2K | |
| 84439 | <1% | 348 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 348 | $2K |
| 64494 | <1% | 43 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 27 | $2K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,469 | $2K |
| 99173 | <1% | 90 | $2K | |
| 11056 | <1% | 55 | $2K | |
| 82947 | <1% | 369 | $1K | |
| 90734 | <1% | 147 | $1K | |
| 51701 | <1% | 39 | $1K | |
| 0003A | <1% | 31 | $1K | |
| 82570 | <1% | 316 | $1K | |
| 99285 | Emergency room visit (most serious) | <1% | 28 | $1K |
| 87081 | <1% | 241 | $1K | |
| 0053A | <1% | 30 | $1K | |
| 95924 | <1% | 13 | $1K | |
| 90744 | <1% | 287 | $1K | |
| 90746 | <1% | 19 | $978.58 | |
| 73140 | <1% | 46 | $969.08 | |
| 99253 | <1% | 14 | $930.16 | |
| 0074A | <1% | 24 | $922.31 | |
| 77080 | <1% | 12 | $792.23 | |
| 92586 | <1% | 15 | $767.04 | |
| V5266 | Battery for use in hearing device | <1% | 59 | $686.98 |
| 97166 | <1% | 13 | $686.26 | |
| 11719 | <1% | 249 | $671.59 | |
| 90685 | <1% | 198 | $654.50 | |
| 83540 | <1% | 173 | $624.25 | |
| 82607 | <1% | 73 | $613.70 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 194 | $613.35 |
| 76536 | <1% | 12 | $567.46 | |
| 87338 | <1% | 44 | $561.26 | |
| 51798 | <1% | 103 | $484.61 | |
| 83550 | <1% | 103 | $479.49 | |
| 84460 | <1% | 91 | $468.21 | |
| 87186 | <1% | 75 | $425.94 | |
| 0073A | <1% | 12 | $423.96 | |
| 84450 | <1% | 73 | $410.42 | |
| 92136 | <1% | 15 | $401.61 | |
| 90672 | <1% | 12 | $364.69 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 25 | $347.09 |
| 72040 | <1% | 15 | $326.23 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12 | $313.06 |
| 92133 | <1% | 12 | $293.64 | |
| 73560 | <1% | 19 | $291.84 | |
| 86780 | <1% | 43 | $290.04 | |
| 94060 | <1% | 14 | $281.10 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 269 | $222.34 |
| 90620 | <1% | 12 | $207.18 | |
| 82043 | <1% | 53 | $199.57 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $188.80 |
| 81002 | <1% | 72 | $187.79 | |
| 95251 | <1% | 15 | $166.24 | |
| 87077 | <1% | 36 | $159.35 | |
| 81015 | <1% | 43 | $151.99 | |
| 87070 | <1% | 21 | $149.05 | |
| 86762 | <1% | 14 | $147.19 | |
| 94729 | <1% | 16 | $135.17 | |
| 99406 | <1% | 110 | $132.56 | |
| 90696 | <1% | 39 | $123.72 | |
| 94726 | <1% | 14 | $101.10 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 16 | $79.04 |
| 83615 | <1% | 14 | $66.78 | |
| 86850 | <1% | 14 | $54.14 | |
| 90710 | <1% | 15 | $46.41 | |
| 86140 | <1% | 13 | $43.67 | |
| 90687 | <1% | 13 | $43.38 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 41 | $39.67 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 294 | $38.63 |
| 86900 | <1% | 12 | $32.41 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 45 | $28.21 |
| 0399T | <1% | 25 | $10.40 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 62 | $7.89 |
| 91312 | 0% | 359 | $0.00 | |
| 91311 | 0% | 12 | $0.00 | |
| 91300 | 0% | 256 | $0.00 | |
| 91307 | 0% | 63 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 26 | $0.00 |
| 91305 | 0% | 192 | $0.00 | |
| 91301 | 0% | 34 | $0.00 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 0% | 16 | $0.00 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 45 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNELSON, NAN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Aurora Medical Group, INC. | Milwaukee, WI | $3.18M |
| Aurora Health Care Metro, INC. | Milwaukee, WI | $2.11M |
| Aurora Bay Area Medical Group LLC | Marinette, WI | $555K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.